Welcome to our dedicated page for ACRX news (Ticker: ACRX), a resource for investors and traders seeking the latest updates and insights on ACRX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ACRX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ACRX's position in the market.
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) announced that an abstract titled "Experience in Complex Outpatient Plastic Surgery Procedures Using Sufentanil Sublingual Tablets" has been accepted for podium presentation at Plastic Surgery: The Meeting 2022 from October 27-30, 2022, in Boston, MA. The presentation will occur in-person with no virtual option. AcelRx focuses on innovative therapies for medically supervised settings, with its product DSUVIA® (sufentanil sublingual tablet) approved for acute pain management in certified healthcare settings.
AcelRx Pharmaceuticals (Nasdaq: ACRX) announced the acceptance of an abstract titled "The Impact of Sublingual Sufentanil on Postoperative Pain Control in Patients Undergoing Spine Surgery" for e-Abstract presentation at the ANESTHESIOLOGY 2022 annual meeting from October 21-25, 2022, in New Orleans, LA. This presentation will be available to registrants virtually and during the event. AcelRx aims to enhance its profile in pain management with its product, DSUVIA, an innovative sublingual opioid analgesic, providing rapid pain relief in medically supervised settings.
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) will release its second quarter financial results on August 11, 2022, after market close. A live webcast and conference call will follow at 4:30 p.m. EDT to discuss the results and business updates. Investors can access the webcast through the company's website, with a replay available for 90 days. AcelRx focuses on innovative therapies, including its approved product, DSUVIA®, and several product candidates aimed at managing severe pain and other medical conditions.
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) announced that CEO Vince Angotti will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, FL. Angotti's presentation is scheduled for May 24 at 3:30 PM EDT, available through a live webcast. The recorded session will be accessible for 90 days on AcelRx's website. AcelRx focuses on developing innovative therapies for medically supervised settings, with its approved product, DSUVIA, managing acute pain in clinical environments.
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) announced modifications to the FDA's DSUVIA Risk Evaluation and Mitigation Strategies (REMS) requirements. The FDA has eliminated the 6-month healthcare setting audit and reduced annual audits to a maximum of 400 sites that received DSUVIA shipments in the last six months. This change reflects AcelRx's compliance and safety record, which includes no accidental exposures. DSUVIA is a sublingual opioid analgesic approved for severe acute pain in medically supervised settings.
AcelRx Pharmaceuticals (ACRX) reported its Q1 2022 financial results, highlighting a net loss of $8.7 million, or $0.06 per share. The company achieved 64% sales growth of DSUVIA compared to the previous quarter, with unit sales reaching 10,530. AcelRx recently acquired Lowell Therapeutics, enhancing its late-stage pipeline with Niyad™, which targets anticoagulation and has Breakthrough Device Designation from the FDA. A cost restructuring is expected to save $9 million annually, while cash reserves stand at $39.3 million as of March 31, 2022.
AcelRx Pharmaceuticals (NASDAQ: ACRX) announced findings from an investigator-initiated trial demonstrating that the sufentanil sublingual tablet (SST) significantly reduced opioid intake in patients undergoing plastic surgery. The study revealed that SST patients required over five-fold less opioids post-surgery compared to those receiving standard IV opioids. Conducted on 61 patients, results indicated 16.4% of SST patients needed rescue opioids in recovery, compared to 90.6% in the control group. The findings support the clinical benefits of SST, including reduced nausea and comparable discharge times.
AcelRx Pharmaceuticals (Nasdaq: ACRX) will release its Q1 2022 financial results before the market opens on May 16, 2022. A live webcast and conference call hosted by management will begin at 8:30 a.m. ET to discuss the financial results and provide business updates. The webcast can be accessed via their website. AcelRx specializes in innovative therapies for medically supervised settings, with products including DSUVIA and several investigational candidates.
AcelRx Pharmaceuticals (NASDAQ: ACRX) announced a Key Opinion Leader webinar on May 4, 2022, at 1:00 PM EDT. The event will focus on the company's late-stage product candidate, Niyad™, a regional dialysis anticoagulant that has received FDA Breakthrough Device Designation. Niyad, already approved in Japan and Korea, aims to prevent clotting in dialysis machines. Experts Stuart Goldstein, MD, and Lakhmir Chawla, MD, will discuss the unmet medical need for such treatments in the U.S.
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) announced results from a podium presentation at The Aesthetic Meeting 2022, highlighting the efficacy of DSUVIA® (sufentanil sublingual tablet) in minimally invasive plastic surgery. The study involved 124 patients, showing that control patients required over five times more IV morphine than those treated with DSUVIA. The recovery time for SST-treated patients was significantly shorter, and adverse effects were minimal, indicating DSUVIA's potential to enhance postoperative pain management.
